Literature DB >> 7514998

Complex formation by human insulin-like growth factor-binding protein-3 and human acid-labile subunit in growth hormone-deficient rats.

M S Lewitt1, H Saunders, J L Phuyal, R C Baxter.   

Abstract

Insulin-like growth factor-binding protein-3 (IGFBP-3), after first associating with IGF-I or IGF-II, is able to associate with the acid-labile subunit (ALS) and form a 140-kDa complex. To investigate the factors regulating ternary complex formation in vivo, human (h) IGFBP-3, hIGF-I, and hALS were administered in various combinations to GH-deficient (dw/dw) rats. hIGFBP-3 had a complex pattern of disappearance from the rat circulation, with an initial phase lasting minutes and a prolonged phase(s) lasting hours. If coinjected with hIGF-I, significantly more hIGFBP-3 was retained over 2 h. The molecular distribution of hIGFBP-3 was determined after size-separation chromatography. After an iv bolus of hIGFBP-3, 36.1 +/- 5.0% was in the 140-kilodalton complex at 5 min; this increased to 55.1 +/- 7.1% if hIGF-I was coinjected (P < 0.05). The 140-kDa complex disappeared slowly over hours, whereas 50- and 30-kDa forms of hIGFBP-3 cleared rapidly, with half-lives of minutes. To determine the importance of ALS in regulating the molecular distribution of hIGFBP-3, hALS was coinjected. Immunoreactive hALS disappeared slowly from the circulation and was shown to retain functional activity after 2 h in vivo. Coadministration of hALS did not influence the pattern of ternary complex formation, consistent with the presence of excess endogenous rat ALS. We conclude that ALS circulates in excess even in GH deficiency, is retained in the circulation for hours, and determines the stability of the 140-kDa complex, whereas IGF-I is a limiting factor in ternary complex formation by hIGFBP-3.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7514998     DOI: 10.1210/endo.134.6.7514998

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  10 in total

1.  D440N mutation in the acid-labile subunit of insulin-like growth factor complexes inhibits secretion and complex formation.

Authors:  Sue M Firth; Xiaolang Yan; Robert C Baxter
Journal:  Mol Endocrinol       Date:  2010-12-22

Review 2.  Insulin-like growth factor 1 (IGF-1): a growth hormone.

Authors:  Z Laron
Journal:  Mol Pathol       Date:  2001-10

3.  The effect of different patterns of growth hormone administration on the IGF axis and somatic and skeletal growth of the dwarf rat.

Authors:  Melissa Westwood; Arfa R Maqsood; Mattea Solomon; Andrew J Whatmore; Julian R E Davis; Robert C Baxter; Evelien F Gevers; Iain C A F Robinson; Peter E Clayton
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-10-27       Impact factor: 4.310

4.  Insulin-like growth factor-binding protein 5 (Igfbp5) compromises survival, growth, muscle development, and fertility in mice.

Authors:  Dervis A M Salih; Gyanendra Tripathi; Cathy Holding; Tadge A M Szestak; M Ivelisse Gonzalez; Emma J Carter; Laura J Cobb; Joan E Eisemann; Jennifer M Pell
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-09       Impact factor: 11.205

5.  Serum insulin-like growth factor (IGF)-I and IGF binding protein-3 in relation to terminal duct lobular unit involution of the normal breast in Caucasian and African American women: The Susan G. Komen Tissue Bank.

Authors:  Hannah Oh; Ruth M Pfeiffer; Roni T Falk; Hisani N Horne; Jackie Xiang; Michael Pollak; Louise A Brinton; Anna Maria V Storniolo; Mark E Sherman; Gretchen L Gierach; Jonine D Figueroa
Journal:  Int J Cancer       Date:  2018-04-01       Impact factor: 7.396

6.  Serum IGF-1 and IGFBP-3 levels in healthy children between 0 and 6 years of age.

Authors:  Bilgin Yüksel; M Nuri Özbek; Neslihan Önenli Mungan; Feyza Darendeliler; Bahar Budan; Aysun Bideci; Ergün Çetinkaya; Merih Berberoğlu; Olcay Evliyaoğlu; Ediz Yeşilkaya; İlknur Arslanoğlu; Şükran Darcan; Ruveyde Bundak; Oya Ercan
Journal:  J Clin Res Pediatr Endocrinol       Date:  2011-06-08

7.  Insulin-like growth factor binding proteins: a structural perspective.

Authors:  Briony E Forbes; Peter McCarthy; Raymond S Norton
Journal:  Front Endocrinol (Lausanne)       Date:  2012-03-02       Impact factor: 5.555

Review 8.  Insulin-Like Growth Factor-1 Deficiency and Cirrhosis Establishment.

Authors:  Rocio G de la Garza; Luis Alonso Morales-Garza; Irene Martin-Estal; Inma Castilla-Cortazar
Journal:  J Clin Med Res       Date:  2017-02-21

Review 9.  IGF-Binding Proteins: Why Do They Exist and Why Are There So Many?

Authors:  John B Allard; Cunming Duan
Journal:  Front Endocrinol (Lausanne)       Date:  2018-04-09       Impact factor: 5.555

Review 10.  Mechanisms of IGF-1-Mediated Regulation of Skeletal Muscle Hypertrophy and Atrophy.

Authors:  Tadashi Yoshida; Patrice Delafontaine
Journal:  Cells       Date:  2020-08-26       Impact factor: 7.666

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.